Moderna (MRNA) Stock Price, News & Analysis

Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $27.62 to $28.30
• 50-Day Range: $25.40 to $34.67
• 52-Week Range: $23.15 to $89.80
• Volume: 2.51 million shs
• Average Volume: 10.71 million shs
• Market Capitalization: $10.84 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.59
• Consensus Rating: Hold

Moderna Stock Analysis - MarketRank™

Moderna scored higher than 91% of companies evaluated by MarketBeat, and ranked 107th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Moderna has received a consensus rating of Hold. The company's average rating score is 2.04, and is based on 3 buy ratings, 16 hold ratings, and 4 sell ratings.

Amount of Analyst Coverage

Moderna has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Moderna are expected to grow in the coming year, from ($9.61) to ($6.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Moderna is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Moderna is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Moderna has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.29% of the float of Moderna has been sold short.

Short Interest Ratio / Days to Cover

Moderna has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Moderna has recently decreased by 4.86%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Moderna does not currently pay a dividend.

Dividend Growth

Moderna does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -2.71

Percentage of Shares Shorted

18.29% of the float of Moderna has been sold short.

Short Interest Ratio / Days to Cover

Moderna has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Moderna has recently decreased by 4.86%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.41

News Sentiment

Moderna has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Moderna this week, compared to 21 articles on an average week.

Search Interest

Only 53 people have searched for MRNA on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.

MarketBeat Follows

19 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 111% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Moderna insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.00% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRNA Stock Analysis - Frequently Asked Questions

How have MRNA shares performed this year?

Moderna's stock was trading at $41.58 at the start of the year. Since then, MRNA shares have decreased by 32.7% and is now trading at $27.9970.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) posted its earnings results on Friday, August, 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. The business's quarterly revenue was down 41.1% on a year-over-year basis.
Read the conference call transcript.

When did Moderna IPO?

Moderna (MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's top institutional investors include Vanguard Group Inc. (10.72%), State Street Corp (4.44%), Geode Capital Management LLC (2.28%) and Theleme Partners LLP (2.02%). Insiders that own company stock include Stephane Bancel, Noubar Afeyan, Stephen Hoge, Shannon Thyme Klinger, Juan Andres, James M Mock and Arpa Garay.
View institutional ownership trends.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 8/01/2025
• Today: 8/19/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRNA
• CIK: 1682852
• Web: www.modernatx.com
• Phone: (617) 714-6500
• Fax: N/A
• Employees: 5,800
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Moderna: $43.59
• High Price Target: $70.00
• Low Price Target: $25.00
• Potential Upside/Downside: +55.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.04
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.56 billion
• Net Margins: -94.31%
• Pretax Margin: -95.68%
• Return on Equity: -25.96%
• Return on Assets: -20.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.93
• Quick Ratio: 3.77

Sales & Book Value

• Annual Sales: $3.24 billion
• Price / Sales: 3.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $28.33 per share
• Price / Book: 0.99

Miscellaneous

• Outstanding Shares: 389,080,000
• Free Float: 346,281,000
• Market Cap: $10.93 billion
• Optionable: Optionable
• Beta: 1.83